Proteolysis-targeting chimeras targeting epigenetic modulators: a promising strategy for oral cancer therapy

References

• 1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 2. Mumtaz M, Bijnsdorp IV, Böttger F et al. Secreted protein markers in oral squamous cell carcinoma (OSCC). Clin. Proteomics 19(1), 4 (2022).
  Medline CASGoogle Scholar
• 3. Swarup N, Hong KO, Chawla K et al. Effect of PAIP1 on the metastatic potential and prognostic significance in oral squamous cell carcinoma. Int. J. Oral Sci. 14(1), 9 (2022).
  Medline CASGoogle Scholar
• 4. Li X, Song Y. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J. Hematol. Oncol. 13(1), 50 (2020).
  Medline CASGoogle Scholar
• 5. Wang C, Zhang Y, Shi L et al. Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents. J. Enzyme Inhib. Med. Chem. 37(1), 1437–1453 (2022).
  Medline CASGoogle Scholar
• 6. He Y, Khan S, Huo Z et al. Proteolysis targeting chimaeras (PROTACs) are emerging therapeutics for hematologic malignancies. J. Hematol. Oncol. 13(1), 103 (2020).
  MedlineGoogle Scholar
• 7. Usman S, Jamal A, Teh MT, Waseem A. Major Molecular Signaling Pathways in Oral Cancer Associated With Therapeutic Resistance. Front. Oral Health. 1, 603160 (2021).
  MedlineGoogle Scholar
• 8. Li X, Pu W, Zheng Q, Ai M, Chen S, Peng Y. Proteolysis-targeting chimaeras (PROTACs) in cancer therapy. Mol. Cancer. 21(1), 99 (2022).
  Medline CASGoogle Scholar
• 9. Chen WC, Chen MF, Lin PY. Significance of DNMT3b in oral cancer. PLOS ONE 9(3), e89956 (2014).
  MedlineGoogle Scholar
• 10. Hsu JH, Rasmusson T, Robinson J et al. EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex. Cell Chem. Biol. 27(1), 41–46.e17 (2020).
  Medline CASGoogle Scholar
• 11. Yamamoto T, Hirosue A, Nakamoto M et al. BRD4 promotes metastatic potential in oral squamous cell carcinoma through the epigenetic regulation of the MMP2 gene. Br. J. Cancer 123(4), 580–590 (2020).
  Medline CASGoogle Scholar
• 12. Qin C, Hu Y, Zhou B et al. Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. J. Med. Chem. 61(15), 6685–6704 (2018).
  Medline CASGoogle Scholar
• 13. Gechijian LN, Buckley DL, Lawlor MA et al. Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nat. Chem. Biol. 14(4), 405–412 (2018).
  Medline CASGoogle Scholar
• 14. Cho YA, Hong JS, Choe EJ et al. The role of p300 in the tumor progression of oral squamous cell carcinoma. J. Oral Pathol. Med. 44(3), 185–192 (2015).
  Medline CASGoogle Scholar
• 15. Sajnani AK, Shah SG, Rashid M, Natu A, Gera PB, Gupta S. In-Silico Analysis of Chromatin Modifiers and Profiling of Histone Deacetylases (HDAC's) in Human Oral Cancer. Chonnam. Med. J. 57(3), 176–184 (2021).
  Medline CASGoogle Scholar
• 16. Carafa V, Altucci L, Nebbioso A. Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype. Front. Pharmacol. 10, 38 (2019).
  Medline CASGoogle Scholar
• 17. Schiedel M, Herp D, Hammelmann S et al. Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals). J. Med. Chem. 61(2), 482–491 (2018).
  Medline CASGoogle Scholar
• 18. Chen L, Wan X, Shan X, Zha W, Fan R. Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy. Mol. Diagn. Ther. 26(3), 283–291 (2022).
  Medline CASGoogle Scholar